Pharmaceutical

Gilead and MSD to advance once-weekly HIV treatment to Phase III

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Oct 24, 2024 - 04:00
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Read the original article

Tags:

Previous Article

A slow start for self-amplifying mRNA vaccines

Next Article

Pharma companies must adapt to keep pace with AI developments, say experts

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Moderna reports net loss of $4.7bn for full year 2023

Moderna reports net loss of $4.7bn for full year 2023

Feb 24, 2024

STAT+: Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss

STAT+: Novo Nordisk sues spas and clinics for selling v...

Jun 20, 2023

STAT+: For Parkinson’s disease, advances spurred by Apple Watch offer a glimmer of hope

STAT+: For Parkinson’s disease, advances spurred by App...

Oct 24, 2023